# Coya Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Coya Therapeutics, Inc.). ## Overview Coya Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies that enhance regulatory T cell (Treg) function to treat neurodegenerative, autoimmune, and metabolic diseases. Its pipeline centers on COYA 301, COYA 302, COYA 303, and exosome-based programs, with a current focus on advancing COYA 302 in ALS and FTD through clinical studies and partnering arrangements. ## Products & services • COYA 302 Treg-enhancing biologic for ALS and FTD • COYA 301 low-dose IL-2 backbone therapy • COYA 303 GLP-1 RA-based program for AD and neurodegeneration • Autologous Treg cell therapy platform • Treg-derived exosome therapeutic research • Sponsored research and development collaborations - **Clinical-stage Treg therapeutics** (100%) — Drug candidates designed to enhance regulatory T cell function in disease. - **Lead program: COYA 302** (0%) — Combination biologic program being advanced in ALS and FTD clinical studies. - **Platform programs: COYA 301 and COYA 303** (0%) — Backbone and follow-on programs intended for combination use and new indications. - **Exosome research** (0%) — Preclinical work on Treg-derived exosomes as a potential therapeutic modality. - COYA 302 Treg-enhancing biologic for ALS and FTD - COYA 301 low-dose IL-2 backbone therapy - COYA 303 GLP-1 RA-based program for AD and neurodegeneration - Autologous Treg cell therapy platform - Treg-derived exosome therapeutic research - Sponsored research and development collaborations ## Customers Coya does not yet sell approved products; its near-term counterparties are clinical investigators, research collaborators, and licensing partners rather than end patients. If approved, its therapies would be used by physicians treating ALS, FTD, Alzheimer’s disease, Parkinson’s disease, autoimmune disease, and potentially metabolic disease patients. The company also relies on third-party payors and reimbursement systems for eventual commercialization. - **Clinical trial patients** (primary) — Patients with ALS and other neurodegenerative diseases enrolled to test safety and efficacy of COYA 302. - **Pharmaceutical licensing partner** (primary) — Dr. Reddy's holds commercialization rights in defined territories and supports development/commercialization of COYA 302. - **Research institutions** (secondary) — Academic and hospital collaborators that support preclinical validation and sponsored research on exosomes and Tregs. - **Future physicians and payors** (emerging) — Specialists and reimbursement bodies that would determine adoption and access if products are approved. - ALS and FTD patients enrolled in COYA 302 clinical trials - Neurologists and specialty physicians treating neurodegenerative disease - Research collaborators such as Houston Methodist Hospital - Licensing partner Dr. Reddy's for ex-U.S. commercialization rights - Third-party payors that would reimburse any approved therapy ## Geography Coya is headquartered in the United States and conducts its core development work there. Its disclosed commercial rights for COYA 302 span the U.S., Canada, the European Union, the United Kingdom, and other ex-U.S. territories through licensing arrangements, while Japan, Mexico, and South America are also referenced in its territorial structure. Because the company is pre-commercial, geography mainly affects where trials, licensing rights, and future reimbursement pathways are concentrated. - United States is the main operating base and clinical-development center - COYA 302 rights cover the U.S., Canada, EU, and U.K. via DRL - Additional territories include Japan, Mexico, and South America - No product sales yet, so geography is driven by R&D and licensing - Future commercialization will depend on local approvals and payor access ## Strategy Coya’s strategy is to build a Treg-focused pipeline across neurodegenerative and autoimmune diseases, with COYA 302 as the lead clinical asset. It is also trying to extend the platform through COYA 301, COYA 303, and exosome programs while using partnerships and licensing to reduce development burden and broaden reach. - **Advance COYA 302 clinical development in ALS** (short-term) — This is the company’s principal near-term value driver and the most advanced program. - **Expand COYA 302 into adjacent neurodegenerative diseases** (medium-term) — Broader indications could increase the commercial opportunity for the same platform. - **Develop COYA 301 and COYA 303 as combination/backbone assets** (medium-term) — These programs are intended to create a modular pipeline and support future combinations. - **Use partnerships and grants to conserve capital** (short-term) — The company is pre-revenue and needs external funding to extend runway and de-risk development. - Advance COYA 302 in ALS through the ALSTARS Phase 2 trial - Explore COYA 302 in FTD, Parkinson's disease, and Alzheimer's disease - Develop COYA 303 through IND-enabling work and external funding - Use COYA 301 as a combination backbone across multiple indications - Pursue partnering and licensing to share development and commercialization risk - Validate exosome therapies through Houston Methodist collaboration ## Risks Coya is a clinical-stage company with no approved products, so its value depends on successful trial outcomes, regulatory approvals, and eventual reimbursement. It also faces financing risk because it has ongoing losses and will need additional capital, plus execution risk from reliance on third-party licensors, manufacturers, and collaborators. - **Clinical development failure** [critical] — COYA 302 and other programs are investigational and may not show efficacy or safety in later studies. - **Financing and going-concern risk** [high] — The company has recurring losses and will need substantial additional capital to continue development. - **Dependence on licensed intellectual property** [high] — Key programs rely on third-party licenses; termination or unfavorable terms could impair the pipeline. - **Manufacturing and supply-chain dependence** [medium] — Programs depend on specialized vendors and equipment for cell therapy and exosome work. - **Reimbursement and market-access uncertainty** [medium] — Even if approved, uptake will depend on coverage, pricing, and payor acceptance. - No approved products, so all value depends on clinical and regulatory success - Trial failure or delays could materially reduce pipeline value - Additional capital will be needed and may not be available on acceptable terms - Reliance on licensed IP and partners creates dependency and termination risk - Manufacturing and supply-chain dependencies can disrupt development timelines - Future commercialization will depend on payor coverage and reimbursement ## Accounting The company’s reported revenue comes from collaboration and license accounting under the DRL arrangement, so timing of milestone and service recognition can create volatility. R&D spending is expensed as incurred and includes preclinical, clinical, CRO/CMO, and sponsored research costs, making quarterly results sensitive to trial timing and development milestones. It also uses judgmental estimates for accrued R&D and stock-based compensation inputs, which can materially affect reported expenses and liabilities. - **Collaboration revenue recognition** — Can cause lumpy quarterly revenue and margin volatility - **Accrued research and development expenses** — Affects operating expenses and current liabilities - **Stock-based compensation valuation** — Can materially affect G&A and R&D expense - **Going-concern assessment** — Important for evaluating runway and capital risk - Collaboration revenue depends on DRL license and R&D service milestones - Revenue recognition timing can create large quarter-to-quarter swings - R&D is expensed as incurred, including CRO, CMO, and sponsored research - Accrued R&D estimates affect liabilities and operating expense timing - Stock-based compensation relies on valuation assumptions and volatility inputs --- *Last updated: 2026-04-28T19:59:29.471231+00:00*